hims glp-1 & Hers swings to a loss in Q1 amid shift in strategy Get after your goal weight

With incretin-based drugs, much of the reported lean mass loss may not be skeletal muscle, but some is

The GLP-1 receptor agonist market is experiencing significant growth, driven by the increasing prevalence of type 2 diabetes and obesity, and the high...

Purpose of Review GLP-1 receptor agonists (GLP-1RAs) have become central therapies for obesity and metabolic disease

New analysis suggests that negotiated pricing still falls short of achieving cost neutrality if GLP-1 drug coverage expands to include weight management.

Glucagon-like peptide-1 (GLP-1) is an incretin peptide hormone mainly secreted by enteroendocrine intestinal L-cells

As a plan sponsor, you have likely had conversation with your benefits consultant on how to pay for these in-demand $900-$1,300 per member per month medications.Scriptas proprietary AI platform has revealed a trend emerging in the dynamic landscape of GLP-1 coverage s